Capital Medical Center
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Alzheimer's Disease
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Menopause
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Seniors' Health
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.
  Tweet it! Pin it!
  New Parkinson's Drug Xadago Approved
 
  To help prevent 'off' episodes among users of levodopa/carbidopa

 

WEDNESDAY, March 22, 2017 (HealthDay News) -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but have instances of increased symptoms anyway, a condition doctors call "off" episodes.

An "off" episode, when Parkinson's medication doesn't seem to work well, may include symptoms such as tremor and difficulty walking, the agency said in a news release.

Some 50,000 Americans are diagnosed each year with Parkinson's, and about 1 million Americans have the neurological condition, the FDA said, citing the U.S. National Institutes of Health. Typically diagnosed in people 60 and older, it occurs when brain cells that produce the chemical dopamine become impaired or die.

The absence of enough dopamine leads to lack of smooth, purposeful movement during activities such as walking, eating, writing or shaving, the FDA said.

Xadago's effectiveness was established in a clinical study of 645 people who were taking the Parkinson's drug levodopa but were still having "off" periods. Compared to people who took a placebo, users of Xadago had fewer instances of Parkinson's symptoms, without uncontrolled involuntary movements that doctors call dyskinesia.

Certain people shouldn't take Xadago, including those with severe liver problems, who are taking a cold medication called dextromethorphan, who are taking a so-called MAOI drug or who are taking certain antidepressants, the FDA said.

Xadago's most common side effects included involuntary movement, falls, nausea and insomnia. More serious adverse reactions included worsening high blood pressure, falling asleep during daily activities, hallucinations, psychotic behavior, compulsive behavior, fever and confusion.

The FDA granted approval of Xadago to Newron Pharmaceuticals, based in Milan, Italy.

More information

Visit the FDA to learn more.

  Print
 
 More  FDA Approvals
 
   •  Noctiva Approved for Frequent Urination at Night
  For adults who awaken to urinate at least twice nightly
 
   •  Xermelo Approved for Tumor-Related Diarrhea
  Drug will treat a condition called carcinoid syndrome diarrhea
 
   •  Siliq Approved for Plaque Psoriasis
  Injected drug is for use by patients who've failed other treatments
 
   •  Emflaza Approved for Duchenne Muscular Dystrophy
  First U.S. approval of corticosteroid to treat the disorder
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2010 CAPITAL MEDICAL CENTER · 3900 CAPITAL MALL DRIVE SW · OLYMPIA, WA 98502 · 360-754-5858 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS